KYTX (Kyverna Therapeutics) LT-Debt-to-Total-Asset: 0.12 (As of Mar. 2026)


KYTX Kyverna Therapeutics Inc KYTX
12 GF Score
Price $8.88
! 1 Warning Sign
View Full Analysis

What is Kyverna Therapeutics LT-Debt-to-Total-Asset?

Kyverna Therapeutics KYTX +5.21% 12 LT-Debt-to-Total-Asset is 0.12 as of Mar. 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Kyverna Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.12.

Kyverna Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.01) to Mar. 2026 (0.12). It may suggest that Kyverna Therapeutics is progressively becoming more dependent on debt to grow their business.

Kyverna Therapeutics  (NAS:KYTX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Kyverna Therapeutics LT-Debt-to-Total-Asset Related Terms

Kyverna Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Kyverna Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics LT-Debt-to-Total-Asset Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
0.06 0.12 0.08 0.01 0.09

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.09 0.12
KYTX
12GF Score
Kyverna Therapeutics Inc KYTX
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyverna Therapeutics LT-Debt-to-Total-Asset Calculation

Kyverna Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=25.063/293.826
=

Kyverna Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=31.77/257.024
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.12 mean?
Kyverna Therapeutics (KYTX) has a LT-Debt-to-Total-Asset of 0.12 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Kyverna Therapeutics and its competitors.
Is Kyverna Therapeutics' LT-Debt-to-Total-Asset too high?
Kyverna Therapeutics' current LT-Debt-to-Total-Asset is 0.12. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' LT-Debt-to-Total-Asset compare to ZURA and CBIO?
Kyverna Therapeutics' LT-Debt-to-Total-Asset of 0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current LT-Debt-to-Total-Asset is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current LT-Debt-to-Total-Asset of 0.12. The current LT-Debt-to-Total-Asset is 0.12. Kyverna Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current LT-Debt-to-Total-Asset is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kyverna Therapeutics Business Description

Address 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score

Get the complete analysis for KYTX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.88
Price